Cell line · CVCL_1395
Papers56
1 to 20 of 56
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| BGN/MDK Axis in the Melanoma Tumor Microenvironment Strengthens Tumor Malignancy by Modulating Cancer Cells and Cancer-Associated Fibroblasts Crosstalk. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Circulating memory B-cell receptor repertoire analysis identifies novel candidate antibodies against metastatic melanoma in immunotherapy-responsive patients. | Front Immunol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| In vitro detection of canine anti-human antibodies following intratumoral injection of the hu14.18-IL2 immunocytokine in spontaneous canine melanoma. | PLoS One | 2025 | Its Methods give the RRID and name the line | PubMed | |
| HTS384 NCI60: The Next Phase of the NCI60 Screen. | Cancer Res | 2024 | Cellosaurus cites it, and its Methods give the RRID and name the line | PubMed | |
| Susceptibility of Melanoma Cells to Targeted Therapy Correlates with Protection by Blood Neutrophils. | Cancers (Basel) | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Bioinformatics-based analysis reveals elevated CYTL1 as a potential therapeutic target for BRAF-mutated melanoma. | Front Cell Dev Biol | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Targeting tumor vasculature to improve antitumor activity of T cells armed ex vivo with T cell engaging bispecific antibody. | J Immunother Cancer | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Overcoming tumor heterogeneity by ex vivo arming of T cells using multiple bispecific antibodies. | J Immunother Cancer | 2022 | Its Methods give the RRID and name the line | PubMed | |
| Modulating tumor infiltrating myeloid cells to enhance bispecific antibody-driven T cell infiltration and anti-tumor response. | J Hematol Oncol | 2021 | Its Methods give the RRID and name the line | PubMed | |
| Quantitative Proteome Landscape of the NCI-60 Cancer Cell Lines. | iScience | 2019 | Cellosaurus cites it | PubMed | |
| Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens. | Nature | 2019 | Cellosaurus cites it | PubMed | |
| An Interactive Resource to Probe Genetic Diversity and Estimated Ancestry in Cancer Cell Lines. | Cancer Res | 2019 | Cellosaurus cites it | PubMed | |
| CAR T cells targeting αvβ3 integrin are effective against advanced cancer in preclinical models. | Adv Cell Gene Ther | 2018 | Its Methods give the RRID and name the line | PubMed | |
| Genetic alterations in main candidate genes during melanoma progression. | Oncotarget | 2018 | Cellosaurus cites it | PubMed | |
| Authentication of M14 melanoma cell line proves misidentification of MDA-MB-435 breast cancer cell line. | Int J Cancer | 2018 | Cellosaurus cites it | PubMed | |
| Characterization of Human Cancer Cell Lines by Reverse-phase Protein Arrays. | Cancer Cell | 2017 | Cellosaurus cites it | PubMed | |
| A map of mobile DNA insertions in the NCI-60 human cancer cell panel. | Mob DNA | 2016 | Cellosaurus cites it | PubMed | |
| A Landscape of Pharmacogenomic Interactions in Cancer. | Cell | 2016 | Cellosaurus cites it | PubMed | |
| Long non-coding RNA expression profiling in the NCI60 cancer cell line panel using high-throughput RT-qPCR. | Sci Data | 2016 | Cellosaurus cites it | PubMed | |
| High resolution copy number variation data in the NCI-60 cancer cell lines from whole genome microarrays accessible through CellMiner. | PLoS One | 2014 | Cellosaurus cites it | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_1395/papers